Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction.

[1]  Harlan M Krumholz,et al.  Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study , 2015, BMJ : British Medical Journal.

[2]  Christopher M. Sandino,et al.  Myocardial T2* mapping: influence of noise on accuracy and precision , 2015, Journal of Cardiovascular Magnetic Resonance.

[3]  R. Blankstein,et al.  Effect of purified omega-3 fatty acids on reducing left ventricular remodeling after acute myocardial infarction (OMEGA-REMODEL study): a double-blind randomized clinical trial) , 2015, Journal of Cardiovascular Magnetic Resonance.

[4]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[5]  G. Fonarow,et al.  International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries☆☆☆ , 2014, International journal of cardiology.

[6]  Brian J. McCourt,et al.  A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. , 2014, JACC. Cardiovascular interventions.

[7]  K. Hirata,et al.  Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. , 2014, Atherosclerosis.

[8]  M. Lauer,et al.  The imperative of overcoming barriers to the conduct of large, simple trials. , 2014, JAMA.

[9]  Paul Heidenreich,et al.  Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. , 2013, Journal of the American College of Cardiology.

[10]  David Erlinge,et al.  Thrombus aspiration during ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[11]  Robert M Califf,et al.  Rescuing clinical trials in the United States and beyond: a call for action. , 2013, American heart journal.

[12]  G. Tognoni,et al.  Exploratory Analysis on the Use of Statins with or without n-3 PUFA and Major Events in Patients Discharged for Acute Myocardial Infarction: An Observational Retrospective Study , 2013, PloS one.

[13]  E. Ntzani,et al.  Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. , 2012, JAMA.

[14]  P. Pérez-Martínez,et al.  Long chain omega-3 fatty acids and cardiovascular disease: a systematic review , 2012, British Journal of Nutrition.

[15]  R. Califf,et al.  Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial , 2012, Circulation. Cardiovascular quality and outcomes.

[16]  P. Galan,et al.  Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial , 2010, BMJ : British Medical Journal.

[17]  G. Steinbeck,et al.  OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction , 2010, Circulation.

[18]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[19]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  C. Lavie,et al.  Omega-3 polyunsaturated fatty acids and cardiovascular diseases. , 2009, Journal of the American College of Cardiology.

[21]  R. Califf,et al.  Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. , 2008, JACC. Cardiovascular interventions.

[22]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[23]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[24]  L. Tavazzi,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002 .

[25]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[26]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .